← Back to Analyst Consensus 
NMRA Buy
Neumora Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 15
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Next Earnings
Nov 4, 2026 (9 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jul 13, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jun 18, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Jun 16, 2026 | Needham | maintain | Buy → Buy | — | 50% |
| Jun 16, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Mar 31, 2026 | Guggenheim | reiterate | Buy → Buy | — | 52% |
| Mar 31, 2026 | Needham | reiterate | Buy → Buy | — | 50% |
| Feb 17, 2026 | William Blair | upgrade | Market Perform → Outperform | $0 | 48% |
| Jan 12, 2026 | Leerink Partners | initiate | — → Outperform | $8 | 50% |
| Dec 1, 2025 | RBC Capital | upgrade | Sector Perform → Outperform | $7 | 55% |
| Nov 17, 2025 | Stifel | maintain | Hold → Hold | $3 | 53% |
| Oct 28, 2025 | Needham | maintain | Buy → Buy | $8 | 50% |
| Oct 27, 2025 | Guggenheim | upgrade | Neutral → Buy | $14 | 52% |
| Sep 16, 2025 | JP Morgan | downgrade | Neutral → Underweight | $0 | 55% |
| Jul 16, 2025 | Mizuho | maintain | Outperform → Outperform | $5 | 52% |
| May 13, 2025 | Needham | reiterate | Buy → Buy | $5 | 50% |
| Apr 10, 2025 | Needham | reiterate | Buy → Buy | $5 | 50% |
| Apr 2, 2025 | B of A Securities | downgrade | Buy → Underperform | $1 | 53% |
| Mar 10, 2025 | Guggenheim | downgrade | Buy → Neutral | $0 | 52% |
| Mar 7, 2025 | Stifel | downgrade | Buy → Hold | $2 | 53% |
| Mar 7, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $18 | 44% |
| Mar 4, 2025 | RBC Capital | reiterate | Sector Perform → Sector Perform | $4 | 55% |
| Mar 4, 2025 | Needham | reiterate | Buy → Buy | $5 | 50% |
| Mar 4, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $18 | 44% |
| Feb 14, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Jan 6, 2025 | B of A Securities | maintain | Buy → Buy | $7 | 53% |
| Jan 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Jan 2, 2025 | Needham | reiterate | Buy → Buy | $23 | 50% |
| Dec 16, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Nov 22, 2024 | RBC Capital | reiterate | Outperform → Outperform | $29 | 55% |
| Nov 13, 2024 | HC Wainwright & Co. | reiterate | Buy → Buy | $30 | 44% |
| Nov 13, 2024 | Needham | reiterate | Buy → Buy | $23 | 50% |
| Nov 5, 2024 | JP Morgan | downgrade | Overweight → Neutral | $15 | 55% |
| Oct 18, 2024 | Needham | reiterate | Buy → Buy | $23 | 50% |
| Oct 1, 2024 | HC Wainwright & Co. | initiate | — → Buy | $30 | 44% |
| Sep 12, 2024 | Needham | reiterate | Buy → Buy | $23 | 50% |
| Sep 4, 2024 | RBC Capital | reiterate | Outperform → Outperform | $29 | 55% |
| Aug 7, 2024 | Needham | reiterate | Buy → Buy | $23 | 50% |
| Jul 22, 2024 | Needham | initiate | — → Buy | $23 | 50% |
| Jul 8, 2024 | Mizuho | initiate | — → Outperform | $20 | 52% |
| Mar 28, 2024 | RBC Capital | reiterate | Outperform → Outperform | $31 | 55% |
| Mar 18, 2024 | JP Morgan | maintain | Overweight → Overweight | $22 | 55% |
| Mar 8, 2024 | RBC Capital | maintain | Outperform → Outperform | $31 | 55% |
| Nov 8, 2023 | JP Morgan | maintain | Overweight → Overweight | $20 | 55% |
| Oct 10, 2023 | JP Morgan | initiate | — → Overweight | $21 | 55% |
| Oct 10, 2023 | B of A Securities | initiate | — → Buy | $18 | 53% |
| Oct 10, 2023 | William Blair | initiate | — → Outperform | $0 | 48% |
| Oct 10, 2023 | Guggenheim | initiate | — → Buy | $22 | 52% |
| Oct 10, 2023 | RBC Capital | initiate | — → Outperform | $24 | 55% |
| Oct 10, 2023 | Stifel | initiate | — → Buy | $26 | 53% |
Price Target Trend
Jun 17, 2026 Latest: $6.14 Oct 25, 2026
EPS Estimates
0q $-0.19
Lo: $-0.21 Hi: $-0.17
9 analysts ▲4
+1q $-0.17
Lo: $-0.20 Hi: $-0.13
9 analysts ▲3
+1y $-0.67
Lo: $-0.97 Hi: $-0.33
9 analysts ▲5
0y $-0.87
Lo: $-0.94 Hi: $-0.65
9 analysts ▲4
Cross-Platform Signals
No cross-platform signals in the last 90 days